About
Glycosylation corrective therapy
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (18)
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
254
By Phase
PHASE2/PHASE3: 1PHASE2: 2
By Status
ACTIVE_NOT_RECRUITING: 2RECRUITING: 1ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06892288Lead Sponsor
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
PHASE2/PHASE3Recruiting
50 participants
Started: Jul 9, 2025 · Completed: Aug 31, 2026
NCT06657859Lead Sponsor
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients
PHASE2Enrolling by invitation
40 participants
Started: Sep 30, 2024 · Completed: Oct 31, 2029
NCT05549219Lead Sponsor
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
PHASE2Active, not recruiting
44 participants
Started: Nov 29, 2022 · Completed: Nov 30, 2025
NCT03173300Lead Sponsor
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
N/AActive, not recruiting
120 participants
Started: Jan 8, 2018 · Completed: Dec 31, 2025
Funding History (1)
D
Nov 10, 2016
Locations (1)
Headquarters
San Carlos, CA, United States
Map
Loading map...